Sanghoon Park is the founder of Illimis Therapeutics. Illimis Therapeutics has raised $63M in total funding. Latest round: Series B.
Sanghoon Park is the Co-founder and CEO of Illimis Therapeutics, a Seoul-based biotech company focused on developing treatments for Alzheimer's disease and immune disorders. He has led the company since its founding in August 2021 and has been instrumental in securing over $63 million in total funding for Illimis.
Full founder directory · Investor directory · Company funding database · Fundraising library